SYNTHETIC PROCEDURES
Prototypical procedure for preparation of 4, 8a-k. Compound 3 was then dissolved in a mixture of 4N NaOH (1.2 mL) and MeOH (5 mL) and the mixture was allowed to heat at 50 ºC for another 2 hours. After the reaction was complete, the mixture was partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous layer was then treated with 6N HCl to pH 2 and the neutral carboxylic acid was extracted into ethyl acetate (2 x 15 mL). After drying over MgSO 4 , removal of organic solvent gave the title compound as an off-white solid (270 mg, 85% over two steps). 1 Prototypical procedure for preparation of 5 and 6. The residue was re-dissolved in ethyl acetate (20 mL) and washed with 0.5 M NaOH and brine sequentially. The organic layer was dried over anhydrous sodium sulphate and concentrated in vacuo, to produce the N-Boc precursor without further purification. The Boc-deprotection was carried out in DCM (1 mL) containing 10%
3-((1-(tert-Butoxycarbonyl)piperidin-4-yl)oxy)thiophene-2-

3-Methoxybenzyl-3-(piperidin-4-yloxy)-thiophene-2-carboxylate
TFA at room temperature for 2 h. After the reaction went to completion, the reaction mixture was evaporated under pressure to dryness, which was further purified by semi-preparative reverse phase HPLC to give the title compound as colourless oil (5 mg, 9% over two steps). 1 1 Reaction mixture was allowed to stir at room temperature for 18 h, then diluted with 0.5 M NaOH (10 mL), followed by extraction with EtOAc (2 x 10 mL).
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Combined organic layers were washed with brine (20 mL), dried over sodium sulfate and concentrated under reduced pressure, yielding pale orange oil which was used without further purification (89 mg). The above orange oil (0.17 mmol) and 1,2,2,6,6-pentamethyl-piperidine (65 μL, 0.36 mmol) in dichloromethane (1 mL) was added TsCl (34 mg, 0.18 mmol) and the reaction mixture was allowed to stir at room temperature for 3 h. The reaction mixture was then diluted with a further 10 mL dichloromethane, washed with water (10 mL), 0.5 M NaOH (10 mL), brine (10 mL), dried over magnesium sulfate and concentrated under reduced pressure. The resulting pale yellow oil was re-dissolved in a solution of DCM (1 mL) containing 10% TFA (v/v). The mixture was stirred at room temperature for 2 hours. The reaction mixture was evaporated under pressure to dryness, which was further purified by semipreparative reverse phase HPLC to give the title compound a colourless oil (28 mg, 35% overall yield). 1 
ASSAYS AND CRYSTALLOGRAPHY
Enzyme assay information. All IC 50 determinations were carried out using a 7-diethylamine-3-(4'maleimidylphenyl)-4-methylcoumarin (CPM) fluorescence assay, as described by previously. [2] [3] [4] The HsNMT1, PfNMT and PvNMT assays are as Macrophage toxicity test. Assays were carried out as described by Paape and colleagues. 6 Briefly, bone marrow-derived macrophage (BMDM, 4.2 × 10 4 /well of 96-well plate) were incubated at the relevant concentrations of test compounds in DMEM medium containing 4% L929 cell and 10% FCS (fetal calf serum). Cells were incubated at 37˚ C and 5% CO 2 for 72 hours. Aalamar blue (10% v/v) was added to each well and the resulting mixture was incubated for additional 4 hours prior to measuring the fluorescence as described above. Medium without cells containing the corresponding concentration of compound was used as a medium control. Assays were performed in duplicate.
Crystallography. Procedure for protein expression, purification, crystallization and data processing were described in detail in an earlier paper. 7 Data refinement can be found in Table S1 . 
